Van de Perre, PhilippeScarlatti, GabriellaMoore, Penny L.Moles, Jean-PierreNagot, NicolasTylleskar, ThorkildGray, Glenda E.Goga, Ameena Ebrahim2024-05-282024-05-282024-03Van de Perre, P., Scarlatti, G., Moore, P.L., et al. Preventing breast milk HIV transmission using broadly neutralizing monoclonal antibodies: one size does not fit all. Immunity, Inflammation and Disease 2024;12:e1216. doi:10.1002/iid3.1216.2050-4527 (online)10.1002/iid3.1216http://hdl.handle.net/2263/96278Passive immunoprophylaxis with broadly neutralizing monoclonal antibodies (bNAbs) could be a game changer in the prevention of human immunodeficiency virus (HIV) acquisition. The prevailing view is that available resources should be focused on identifying a fixed combination of at least three bNAbs for universal use in therapeutic and preventive protocols, regardless of target populations or routes of transmission. HIV transmission through breastfeeding is unique: it involves free viral particles and cell-associated virus from breast milk and, in the case of acute/recent maternal infection, a viral population with restricted Env diversity. HIV transmission through breastfeeding in high incidence/prevalence areas could potentially be eliminated by subcutaneous administration to all newborns of one or two long-acting bNAbs with extended breadth, high potency, and effector properties (ADCC, phagocytosis) against circulating HIV strains.en© 2024 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License.Antibodies moleculesHuman animalsViral infectionRetroviral infectionBreast milkHuman immunodeficiency virus (HIV)HIV transmissionSDG-03: Good health and well-beingArticle